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Abstract
Background: High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading
to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a
larger proportion of patients. However, not all patients respond to immune checkpoint blockade and subsequent
therapeutic options need to be explored.
Methods: The PROCLAIM database was queried for patients with metastatic melanoma who had received HD IL-2
after treatment with ipilimumab or without prior ICB. Patient characteristics, toxicity and efficacy were analyzed.
Results: A total of 52 metastatic melanoma patients were treated with high dose IL-2 after ipilimumab and 276
patients were treated with high dose IL-2 without prior ICB. The overall response rate in the prior ipilimumab
group was 21 % as compared to 12 % in the group that had not received prior ipilimumab. The median overall
survival, measured from the initiation of HD IL-2 therapy, was 19.3 months in the prior ipilimumab group and 19.
4 months in the no prior ICB group. Toxicities observed on HD IL-2 were relatively equivalent between the
groups although there were cases of CTLA4 antibody-induced colitis reported after HD IL-2 treatment and a
CTLA4 antibody-induced colitis related death.
Conclusion: In this retrospective analysis HD IL-2 therapy displayed antitumor activity in melanoma patients
who progressed following treatment with ipilimumab. Most HD IL-2 toxicity was not worsened by prior ipilimumab
therapy except for one treatment related death from colitis. Care should be taken to avoid reactivation of CTLA4
antibody-induced colitis.
Keywords: Melanoma, Interleukin-2, Immune Checkpoint blockade, Ipilimumab
Background
Immunotherapy has become the backbone of melanoma
therapy and is rapidly expanding its role in renal cell car-
cinoma, lung cancer and other malignancies. Since 2011,
three novel immune checkpoint blockade agents have been
approved for the treatment of advanced melanoma and are
recommended among the first line options for treatment
[1–5]. However, there remain patients who do not respond
to front line immune checkpoint blockade who require
further treatment. For several decades, cytokine based
immunotherapies such as high dose interleukin-2 (HD
IL-2) have been shown to induce durable tumor responses
in a subset of patients leading to long-term survival [6].
However, the toxicity profile of HD IL-2 is high which
limits its application [7].
Regulation of the immune system is complex and in-
volves a number of regulatory checkpoints, growth factors,
cytokines and regulatory immune cells that play a role in
host anti-tumor immunity. A key observation in the clinic
is that lack of response to one immune checkpoint inhibi-
tor class such as CTLA-4 blockade does not predict for
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lack of response to anti PD-1 therapy [3, 5]. The use of
HD IL-2 therapy following immune checkpoint blockade,
particularly the impact on therapeutic response and po-
tential toxicity, needs to be investigated further in the
context of the rapidly changing field of immuno-oncology.
There have been prior reports of colitis and bowel per-
foration in patients receiving IL-2 therapy following
ipilimumab [8].
In addition, understanding the interaction between im-
munotherapies will help guide future combinations and
sequencing of these agents. In this study we queried the
PROCLAIM (Additional file 1) database for patients with
advanced malignant melanoma who had received HD IL-2
following treatment with ipilimumab and compared them




PROCLAIM (Additional file 1) is an IL-2 patient database
with >40 participating sites consisting of a retrospective
melanoma (n = 170, locked) and prospective melanoma
cohort (n >335, on-going). The registry is designed to
collect data from community and large academic centers
on the use of HD IL-2 in the treatment of metastatic renal
cell carcinoma (mRCC) or metastatic melanoma (mM)
(Clinicaltrials.gov: NCT 01415167) For this study, the pro-
spective cohort was queried to identify patients treated
with HD IL-2 after receiving ipilimumab. Patient charac-
teristics, including age, gender, disease type, number and
type of prior therapies, duration of ipilimumab therapy
and toxicity associated with therapy are reported.
Treatment
HD IL-2 was administered per the treating institution’s
standard of care as an inpatient regimen, typically utiliz-
ing a 600,000 IU/kg or 720,000 IU/kg IV infusion every
8 hours as tolerated up to 14 consecutive doses over
5 days. Patients were readmitted for a second week/cycle
of treatment after approximately 9 days off therapy, per
the discretion of the treating physician. Two weeks of
HD IL-2 therapy constituted one course of treatment.
Ipilimumab was administered to patients either as part
of a clinical trial or as standard of care therapy at the
FDA approved dose and schedule of 3 mg/kg intraven-
ously every three weeks for up to four doses. Eleven of
the patients treated on clinical trial were noted to have
received more than 3 months of ipilimumab therapy and
thus also received maintenance ipilimumab.
Response data and adverse events
Toxicities in patients treated with HD IL-2 after receiving
ipilimumab were examined and compared to subjects who
received HD IL-2 without receiving prior ipilimumab. The
average number of IL-2 doses per week is also reported.
The number of patients who achieved a complete re-
sponse (CR), partial responses (PR), stable disease (SD)
and progressive disease (PD) as determined by the treating
physician using RECIST or modified WHO criteria is re-
ported. Objective response rate (ORR) and median overall
survival (OS) are also reported. Response and survival
endpoints were measured from the start of HD IL-2 ther-
apy and were compared amongst patients who did and
those who did not receive prior ipilimumab.
Statistical analysis
All statistical analyses were performed using SAS software
version 9.4 (SAS Institute, Cary, NC). Patient characteris-
tics, tumor response, and survival status were determined
using data as of December 2nd, 2015. Frequency counts
and measures of central tendency were performed to pro-
vide descriptive statistics; medians were reported with the
minimum and maximum values. A chi-squared test was
performed for toxicities observed during cycle 1. Kaplan-
Meier curves with 95 % confidence intervals (CIs) were
used to estimate median overall survival (mOS) (the
primary outcome), with the log-rank test to determine
significance (P < .05). Overall survival time was calcu-
lated from the date of first dose of HD IL-2 to either
the date of death or date of most recent follow-up. The
ORR was calculated from the summation of patients
reporting CR + PR divided by the total number of pa-
tients. The relationship between ipilimumab response




A total of 328 patients were identified within the registry
that fit the search criteria. 276 metastatic melanoma
patients were treated with HD IL-2 without prior im-
mune checkpoint blockade. Fifty-two metastatic melan-
oma patients were treated with ipilimumab prior to IL-2.
Patients in both groups were predominantly male with
ECOG performance status of O or 1 and had greater than
or equal to 3 metastases (Table 1). Prior immunotherapy
(predominantly adjuvant interferon) was noted in 31 % of
those patients that were not treated with prior immune
checkpoint blockade. LDH levels prior to initiating HD
IL-2 were equivalent between the two groups, mean 291.1
in the prior ipilimumab group and 286.6 in the group
without prior immune checkpoint blockade.
Mutational status was reported for 36 of the prior
ipilimumab only patients and 200 of the patients who
had not received prior immune checkpoint blockade.
Among those patients in whom mutational status was
reported 44 and 57 %, respectively, were noted to be
BRAF mutant in the ipilimumab and no ICB groups,
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17 % and 6 %, respectively, were noted to be NRAS
mutant. Of the patients in who mutational status was
tested there were no cKIT mutations noted among
the patients in the Ipilimumab group and 8 patients
with cKIT mutations in the no prior ICB group.
In the 52 patients who received ipilimumab before HD
IL-2, ipilimumab was the therapy that immediately pre-
ceded HD IL-2 in 38 of the patients. The average time
between completing ipilimumab and starting HD IL-2
was 7.61 months with a range of 1-30.6 months for all
patients previously treated with ipilimumab. For those
patients in whom ipilimumab was the therapy immediate
preceding HD IL-2 therapy; the mean time to HD IL-2
was 6.0 months with a range of 0.4-30 months. On aver-
age patients were on ipilimumab for 3.0 months with a
range of 0.03-25 months prior to stopping ipilimumab.
All patients had progression of their disease prior to
initiating treatment with HD IL-2.
Table 1 Baseline characteristics
Prior Ipi only (n = 52) No prior ICB (n = 276) Total (n = 328)
Sex Female 20 38 % 104 38 % 124 38 %
Male 32 62 % 172 62 % 204 62 %
Age <65 43 83 % 234 85 % 277 84 %
≥65 9 17 % 42 15 % 51 16 %
Median 52 53 53
ECOG 0 35 67 % 190 69 % 225 69 %
1 15 29 % 78 29 % 98 28 %
2 0 3 1 % 3 1 %
Missing 2 4 % 5 1 % 7 2 %
# of metastasis 1 13 25 % 82 30 % 95 29 %
2 20 38 % 92 33 % 112 34 %
≥3 17 33 % 79 29 % 96 29 %
Missing 2 4 % 23 8 % 25 8 %
Prior treatments Surgery 42 81 % 203 74 % 245 75 %
Radiation 20 39 % 84 31 % 104 32 %
Chemotherapy 11 21 % 35 13 % 16 5 %
Immunotherapy 52 100 % 85 31 % 137 42 %
Targeted therapy 9 17 % 7 3 % 46 14 %
Other 2 4 % 4 1 % 6 2 %
No Prior Tx 0 36 13 % 36 11 %
Melanoma Subtype Cutaneous 36 69 % 195 71 % 231 70 %
Mucosal 4 7 % 15 5 % 19 6 %
Ocular 3 5 % 6 2 % 9 3 %
Acral 1 2 % 5 2 % 6 2 %
Unknown 8 15 % 55 20 % 63 19 %
BRAF statusa WT 20 56 % 84 42 % 104 45 %
Mutated 16 44 % 114 57 % 130 54 %
Not done 0 2 1 % 2 1 %
NRASa WT 10 28 % 64 32 % 74 31 %
Mutated 6 17 % 12 6 % 18 8 %
Not done 20 56 % 124 62 % 144 61 %
cKITa WT 16 44 % 84 42 % 103 43 %
Mutated 0 8 4 % 8 4 %
Not done 20 56 % 105 53 % 125 53 %
aMutation status and percentages reported for those patients in whom any mutational testing was reported. For some of these patients only a single genetic test
was performed and these patients are included in the chart but listed as having that particular test not done
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The mean time between diagnosis of metastatic disease
and initiation of HD IL-2 was 18 months (0.2-80) in pa-
tients previously treated with ipilimumab and 7 months
(0.03-98) in patients with no prior ICB. The average drug
administration duration for HD IL-2 (including rest pe-
riods) was 2.0 months for the patients previously treated
with ipilimumab and 1.9 months in the patients who were
not treated with prior ICB, with the majority of patients
receiving only 2 cycles (1 course) of HD IL-2. In the ipili-
mumab treated group 62 % of patients received 2 cycles
and 21 % received four cycles. In the group with no prior
ICB 56 % received 2 cycles and 24 % received 4 cycles.
Toxicity
Adverse events resulting in cessation of HD IL-2 for cycle
1 of treatment are reported in Table 2. The database cap-
tured up to 3 toxicites per patient. The pattern of IL-2
toxicity between the groups was relatively similar with
cardiac, renal, neurologic and GI toxicities being the most
frequently reported. During cycle 1 there was no statis-
tically significant difference observed between the two
groups (p-value = 1). Of note there were more pulmon-
ary toxicites reported in the prior Ipilimumab group
but this difference was not statistically significant. The
cardiac toxicities included hypotension, tachycardia,
arrhythmia, myocarditis, hypertension and fluid overload.
The average number of HD IL-2 doses per cycle is
often used as a reflection of toxicity since IL-2 is held
when a patient is having more severe side effects. While
this can be influenced by the institution’s standard prac-
tice, the fact that similar dose numbers were reached in
the two groups suggests similar toxicity profiles. The aver-
age number of HD IL-2 doses per cycle is summarized in
Table 3.
Institutions involved in PROCLAIM (Additional file 1)
reported several patients with severe HD IL-2 toxicity
that was considered possibly related to prior ipilimumab.
In one case a patient developed increased bloody diar-
rhea after completing IL-2 treatment. Colonoscopy with
biopsy revealed diffuse active colitis with moderate inflam-
mation in the mid sigmoid colon consistent with CTLA4
antibody-related colitis. The patient was started on high
dose steroids with resolution of symptoms. Another pa-
tient developed severe diarrhea during treatment with HD
IL-2 which was resistant to high dose steroid administra-
tion. This patient subsequently developed ischemic colitis,
acidosis anddied. Neither patient had evidence of CTLA-4
antibody-related colitis prior to starting HD IL-2 therapy.
Within the no prior ICB cohort there were two pa-
tients who died during their HD IL-2 therapy. One
patient developed altered mental status felt to be related
to undetected brain metastasis with subsequent respira-
tory failure. The second patient developed respiratory
failure of unclear origin. The database also looks at pro-
longation of hospitalization, disability or permanent dam-
age during HD IL-2 therapy. This was reported in 4 of
the patients treated with prior ipilimumab (11 %) and 8
of the patients with no prior ICB (4 %) during cycle 1.
The toxicities observed in these patients were consist-
ent with those observed with HD IL-2 alone. Within
the database only two ipilimumab treated patients were
reported as having autoimmune toxicity during IL-2 dos-
ing, one with hepatitis and one with myasthenia gravis.
On further investigation these side effects were deter-
mined to be HD IL-2 related and not due to recurrence of
ipilimumab toxicity.
At the post treatment follow up visits evidence of auto-
immune disease was assessed. In the group of patients
treated with ipilimumab prior to HD IL-2 6 patients (11 %)
Table 2 HD IL-2 dose limiting toxicities reported for cycle 1 of treatment
Ipi only (n = 52) No prior ICB (n = 276) Total (n = 328)
Cardiac 13 18.57 84 24.56 97 23.33
Renal 12 17.14 51 14.91 63 15.29
Neurologic 5 7.14 52 15.2 57 13.83
Gastrointestinal 10 14.29 36 10.53 46 11.17
Hematologic 7 10 34 9.94 41 9.76
Metabolic 5 7.14 30 8.77 41 9.76
Pulmonary 10 14.29 19 5.6 29 7.38
Capillary Leak Syndrome 2 2.86 17 4.97 19 4.52
Hepatic 2 2.86 13 3.8 15 3.57
Skin 4 5.71 6 1.75 10 2.38
Total 70 100 342 100 412 100.0
The first column represents the number of times a toxicity was reported among the entire cohort of patients. The second is the percentage of each individual
toxicity as compared to the total number of events. The total events add up to more than the number of patients as some patients reported more than one dose
limiting toxicity, up to a maximum of three
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reported evidence or autoimmune disease. Of these six
patients, 2 had vitiligo, 2 had autoimmune dermatitis, 1
had hemolytic anemia and 1 had autoimmune hepatitis. In
the group of patients who received no prior immune
checkpoint blockade 16 patients (6 %) reported evidence of
autoimmune disease. Of these patients, 5 had thyroid
abnormalities, 3 had colitis, 2 had vitiligo and individ-
ual patients reported dermatitis, hepatitis, encephalop-
athy, Guillain-Barre, Myasthenia Gravis and neuropathy.
These toxicities were reported at follow up visits and
could have been associated with subsequent therapies.
Among the patients treated with ipilimumab prior to HD
IL-2, 19 had subsequent ICB after HD IL-2, 15 patients
had a-PD1 therapy and four patients had combination
ipilimumab and a-PD1 therapy. Among the patients who
had not received ICB prior to HD IL-2, 138 patients had
subsequent ICB after HD IL-2, 84 of these patients re-
ceived ipilimumab alone, 45 patients received a-PD1 ther-
apy alone and 9 patients received combination ipilimumab
and a-PD1 therapy.
Response rates and survival
The median follow up of all patients was 22 months. Of
the patients included in this analysis an overall response
rate of 14 % was observed with 10 of the 328 (3 %) pa-
tients experiencing a complete response (CR) and 35
(10.7 %) experiencing a partial response (PR). When ana-
lyzed by prior treatment group the overall response rate
was 21 % in patients previously treated with ipilimumab
with 1 (1.9 %) of the patients experiencing a CR and 10
of the 52 (19.2 %) patients experiencing a PR. In the
group that had not received prior ICB the overall response
rate was 12 % with 9 of the 276 (3.3 %) experiencing a CR
and 25 (9.1 %) experiencing a PR. Response data is
summarized in Table 4.
Overall survival, measured from the initiation of HD
IL-2 administration, in the group treated with ipilimu-
mab as compared to those patients who had not been
treated with prior ICB was equivalent. The mean overall
survival was 19.3 months (95 % CI: 12.9, NE) in patients
who had received prior ipilimumab as compared to
19.4 months (95 % CI: 15.8, 23.1) in those who had not
received prior ICB (p-value 0.8027). Kaplan-Meier sur-
vival curves are shown for MM both groups in Fig. 1.
Among the patients treated with ipilimumab prior to
HD IL-2 one patient had a PR to ipilimumab, 6 patients
had stable disease (SD) on ipilimumab, 5 patients are
missing data and the remainder of patients had progressive
disease (PD). The patient with a prior PR to ipilimumab
had SD on HD IL-2, those with prior SD on ipilimumab
had outcomes that were varied with one PR, one SD and
four having PD on HD IL-2. There was no statistically sig-
nificant relationship between response to ipilimumab and
response to HD IL-2 (p-value = 0.6612).
Discussion
Preliminary retrospective analysis in patients with ad-
vanced malignant melanoma suggests that HD IL-2 is a
safe treatment option for patients who have had progres-
sive disease after ipilimumab. The overall response rates
and survival benefit of HD IL-2 appears were not statisti-
cally different when comparing patients with prior ipilimu-
mab and those treated front line with HD IL-2 with
ongoing durable responses. In addition overall survival was
similar in the two groups despite the fact that patients who
had previously received ipilimumab were further into their
melanoma treatment, 18 months from diagnosis of meta-
static disease as compared to 7 months in the no prior
ICB patients. It is possible that some of this effect is
due to delayed response to ipilimumab or a synergistic
immune response.
High dose IL-2 therapy has predictable toxicity and
must be administered in an experienced inpatient setting.
In this analysis emergence of CTLA4 antibody induced
colitis in patients treated with HD IL-2 following ipilimu-
mab was seen, consistent with a prior report from the
National Cancer Institute [8]. However, by the database
Table 3 Number of doses received during each cycle of HD IL-2
Cycle Group n Mean Min Max
1 Prior Ipi 52 9.9 3 14
No ICB 276 9.9 1 14
2 Prior Ipi 49 8.2 1 14
No ICB 252 8.2 2 14
3 Prior Ipi 17 8.2 5 12
No ICB 98 8.6 1 14
4 Prior Ipi 17 6.7 2 12
No ICB 88 6.6 2 14
Table 4 Tumor response to HD IL-2
Prior Ipi only n = 52 No prior ICB n = 276 Total n = 328
n % n % n %
CR 1 1.92 9 3.26 10 3.05
PR 10 19.23 25 9.06 35 10.67
SD 15 28.85 74 26.81 89 27.13
PD 23 44.23 158 57.25 181 55.18
Missing 3 5.77 10 3.62 13 3.96
Total 52 100 276 100 328 100
n % n % n %
CR + PR 11 21.15 34 12.32 45 13.72
CR + PR + SD 26 50 108 39.13 134 40.85
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Fig. 1 a Overall survival after treatment with HD IL-2 therapy in patients treated with prior Ipilimumab as compared to those patients not treated
with prior ICB. b Overall survival from the time of diagnosis with metastatic melanoma in patients treated with ipilimumab prior to HD IL-2 as
compared to those patients not treated with prior ICB
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numbers there was no increase in the overall number
of toxicities during HD IL-2 therapy when comparing
patients who have received HD IL-2 front line versus
those receiving it after ICB. We did not observe immune-
mediated hypophysitis in this population, which has been
reported in up to 4 % of patients receiving ipilimumab
monotherapy. In addition, the number of doses patients
received was similar between the two patient populations
suggesting that toxicity during HD IL-2 therapy was not
significantly altered by prior ipilimumab exposure.
The benefit of HD IL-2 therapy is that the side effects
are dose dependent, largely predictable, easily managed
and reversible. IL-2-related mortality is less than 1 % at
experienced treatment centers with more extensive car-
diac screening and better patient selection [7]. However,
physicians administering HD IL-2 following ipilimumab
should be aware of possible anti-CTLA4- related colitis
exacerbation following HD IL-2 therapy since diarrhea is
a common symptom with both HD IL-2 and ipilimumab
treatment. Patients who had evidence of significant prior
CTLA-4 related colitis should only be treated with HD
IL-2 after endoscopic evaluation to ensure resolution of
colitis. In addition, patients who develop persistent (on-
going or increasing after IL-2 dosing) or bloody diarrhea
should undergo diagnostic studies, including stool cul-
tures, CT and/or colonoscopy, to rule out other causes
and evaluate for immune-mediated colitis. In addition
physicians should consider early use of systemic cortico-
steroids or other immunosuppressants to control diarrhea
and avoid colon perforation or death when immune-
mediated colitis is suspected in this clinical setting.
In addition to the potential use of HD IL-2 therapy
following immune checkpoint blockade there is also the
potential for HD IL-2 to be combined with immune check-
point blockade. In a small phase Ib clinical trial evaluating
the combination of HD IL-2 and dose-escalating ipilimu-
mab, an overall response rate of 22 % was reported with
a 8 % complete response rate in a small phase I/II study
[9]. A trial of this combination is ongoing and will help
determine if diverse immunotherapies have potential
synergy (Clinicaltrials.gov: NCT02203604). This analysis is
limited to patients treated with ipilimumab prior to HD
IL-2 with the plan to examine patients treated with PD1
prior to HD IL-2 as more patients are entered into the
database.
There are several limitations of this analysis that may
limit its application to daily practice. Data is entered into
the database prospectively but this analysis is retrospective
and only allows for certain specific data to be captured.
The overall numbers of patients remain small and may
not capture toxicities observed at institutions which do
not participate in PROCLAIM. Investigators could only
enter three dose-limiting HD IL-2 related toxicities per
patient in an attempt to capture the most severe; however,
this may cause an analysis such as this to miss a toxicity
that was less severe but more prevalent in the patients
previously treated with ipilimumab. Patients were assessed
for response by independent investigators using differ-
ent response criteria and this may have influenced the
outcome. Further, ipilimumab has been associated with
delayed kinetics of therapeutic response and so it is
possible that some patients may continue to exhibit
therapeutic anti-tumor activity later in the natural history
of their disease. These issues may explain the slightly
lower response rate reported overall in this trial compared
to historical studies in which HD IL-2 response rates are
usually around 16–17 %.
One area of ongoing active investigation includes bio-
markers to better predict patients who may benefit from
HD IL-2 and immune checkpoint blockade. Numerous
studies are evaluating different possible retrospective and
prospective markers of immune response [10–13]. As
these investigations continue there will be the opportunity
to evaluate patients responding to IL-2 post checkpoint
blockade to better identify those most likely to bene-
fit. In our trial, there did not appear to any influence
on response by tumor mutation status.
Conclusions
Immune checkpoint blockade is rapidly advancing beyond
melanoma into the treatment of renal cell carcinoma, lung
cancer, bladder cancer and many other malignancies. As
this occurs our need to understand how it potentially
interacts with other treatments will be essential to our
ability to administer it safely. In addition we continue to
require options for patients who do not respond to im-
mune checkpoint blockade, but may be candidates for
additional immunotherapy. HD IL-2 remains a viable
treatment in melanoma and may be safely administered
following progression on ipilimumab.
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